Opie’s Cardiovascular Drugs

Description:

Authoritative, portable, and up to date, Opie’s Cardiovascular Drugs, 9th Edition, is the definitive reference for quick access to frequently used drugs in all phases of care for cardiac patients. Now a part of the Braunwald family of renowned cardiology references, this compact title provides crucial information in an easily accessible format—ideal for cardiologists, residents, cardiology fellows, medical students, nurses, and other cardiac care providers. Updated to include the latest guidelines and evidence-based implications, it offers clear and concise explanations and pertinent clinical facts for all classes of cardiac drugs, as well as all the latest clinical trial results and evidence for the pharmacologic treatment of heart disease.

• Uses a new, consistent format for each drug class: overview and guidelines for use, mechanisms of action, differences among drugs in class, data for use, side effects, and drug interactions.
•  Covers key topics such as new ESC and NLA guidelines, advances in lipid-lowering therapy, new diabetes drugs that improve cardiovascular outcomes, obesity drugs and cardiovascular and metabolic effects, drugs targeting inflammation, and combinations of antithrombotic therapies with analysis of risk-benefit.
• Provides guidance on how to effectively manage comorbid diseases.
•  Contains dozens of unique “Opiegram” diagrams that demystify complex mechanisms of action and other drug processes—many updated to reflect current pathologic understanding of mechanisms.

Table of Contents:

1.    Braunwald’s Heart Disease Family of Books

2.    1: Drugs for Ischemic Heart Disease

3.    Introduction

4.    β-Blockers

5.    Summary

6.    Nitrates and Newer (or Nontraditional) Antianginals

7.    Calcium Channel Blockers

8.    Summary

9.    Summary

10.  2: Antihypertensive Therapies

11.  Introduction

12.  Drug Class Overview and Guidelines

13.  Diuretics

14.  Calcium Channel Blockers

15.  Angiotensin-Converting Enzyme Inhibitors

16.  Angiotensin II Receptor Blockers

17.  Mineralocorticoid Receptor Antagonists

18.  β-Blockers

19.  Central Sympatholytic Agents

20.  α1-Adrenoreceptor Antagonists

21.  Direct Vasodilators

22.  3: Heart Failure

23.  Introduction

24.  Acute Decompensated Heart Failure

25.  Pharmacotherapy

26.  Vasodilators

27.  Novel Vasodilators

28.  Inotropes

29.  β-Adrenergic Agonists

30.  Phosphodiesterase Inhibitors

31.  Calcium Sensitizers

32.  Novel Inotropes

33.  Vasopressors

34.  Special Situations

35.  Heart Failure Patients With Reduced Ejection Fraction

36.  Pharmacotherapy

37.  Angiotensin-Converting Enzyme Inhibitors

38.  Angiotensin Receptor Blockers

39.  Angiotensin Receptor Neprilysin Inhibitors

40.  Mineralocorticoid-Receptor Antagonists

41.  Sodium-Glucose Cotransporter-2 Inhibitors

42.  Additional Therapy

43.  Combination of Hydralazine Plus Isosorbide Dinitrate

44.  If Channel Inhibitor

45.  Digoxin

46.  Iron Supplementation and Anemia

47.  Fish Oil and Marine Omega-3 Polyunsaturated Fatty Acids

48.  Micronutrient Supplementation

49.  Oral Anticoagulants and Antiplatelet Therapy

50.  Statins

51.  Antiarrhythmic Agents

52.  Direct Renin Inhibitors

53.  Heart Failure Patients With Preserved Ejection Fraction

54.  Heart Failure Patients With Mid-Range Ejection Fraction

55.  Pharmacotherapy

56.  Renin-Angiotensin Blockade: Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

57.  Mineralocorticoid Receptor Antagonists

58.  Angiotensin Receptor Neprilysin Inhibitors

59.  β-Blockers

60.  Digoxin, Calcium Channel Blockers, and Ivabradine

61.  Nitric Oxide and cGMP Signaling: Phosphodiesterase-5 Inhibitors, Nitrates, and Soluble Guanylate Cyclase Stimulators

62.  Other Medications

63.  Reverse Cardiac Remodeling: Remission Versus Recovery

64.  Drugs That Should Be Avoided or Used Cautiously in Heart Failure

65.  Pharmacological Treatment of Selected Cardiomyopathies

66.  Future Perspectives

67.  Summary

68.  4: Drugs for Diabetes

69.  Metabolic Syndrome and Prediabetes

70.  Diabetes Prevention

71.  Cardiovascular Disease Risk Assessment

72.  Value of Improved Glycemic Control

73.  Importance of Large Cardiovascular Disease Outcome Trials

74.  Drugs That Lower Cardiovascular Disease Risk

75.  Drugs That Do Not Lower Cardiovascular Disease Risk

76.  Hypoglycemia

77.  Guidelines

78.  Future Directions

79.  5: Drugs for Obesity

80.  Drug Class Overview and Guidelines

81.  Weight Loss Intervention

82.  Pathophysiology and Mechanism of Action

83.  Conclusion

84.  6: Lipid-Modifying Drugs

85.  Inflammation and Atherogenesis

86.  Prevention and Risk Factors

87.  Blood Lipid Profile

88.  Lipids in Special Population Groups

89.  Dietary and Other Nondrug Therapy for Dyslipidemia

90.  Drug Therapy for Dyslipidemia

91.  Summary

92.  7: Drugs Targeting Inflammation

93.  Basic Concepts of Inflammation Biology

94.  Stimuli for the Inflammatory Response

95.  Central Hubs of Inflammatory Signaling (see Fig. 7.2)

96.  Mediators

97.  Conclusions, Challenges, and Future Perspective

98.  8: Antithrombotic Drugs

99.  Introduction

100.               Thrombosis

101.               Emerging Construct and Future Targets for Antithrombotic Therapy

102.               Cardiovascular Drug Therapy

103.               Platelet-Directed Therapies

104.               Platelet P2Y12 Receptor Antagonists

105.               Periprocedural Management of Antiplatelet Therapy

106.               Intravenous Platelet GPIIb/IIIa Receptor Antagonists

107.               Summary of Recommendations in Patients With ACS

108.               Anticoagulants

109.               Parenteral Anticoagulant Drugs

110.               Direct Thrombin Inhibitors

111.               Direct FXa Inhibitors

112.               Indirect, Selective FXa Inhibitors

113.               Direct Thrombin Inhibitors

114.               Argatroban

115.               Reversal and Replacement Therapy for Parenteral Anticoagulants

116.               Oral Anticoagulant Drugs

117.               Pharmacokinetics and Drug Disposition

118.               Oral Direct Thrombin Inhibitors

119.               Vitamin K Antagonists

120.               Reversal and Replacement of Direct Oral Anticoagulant Drugs

121.               Achieving Good Hemostasis

122.               Conclusions

123.               9: Antiarrhythmic Drugs

124.               Overview of New Developments

125.               Antiarrhythmic Drugs

126.               Inhaled Agents

127.               New Developments in Antiarrhythmics

128.               Antiarrhythmic Choice for Arrhythmias

129.               Summary

130.               10: Vascular Medicine Drugs

131.               Overview

132.               11: Drugs for Pulmonary Hypertension

133.               Drug Class Overview and Guidelines

134.               Mechanisms of Action

135.               Differences Among Drugs in Class

136.               Data for Use

137.               Side Effects

138.               Drug Interactions

139.               Experimental Drugs

140.               Conclusions

141.               Index